Clinical Trial

A Phase I Study of HW201877 in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 28, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW201877 in healthy subjects following (1) a single ascending dose (Part 1), which includes a single-dose, two-period crossover FE cohort; (2) a multiple ascending dose (Part 2).
Trial Details
NCT Number NCT07373457
Lead Sponsor Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Conditions Healthy Participants, IBD (Inflammatory Bowel Disease)
Enrollment 104 participants
Start Date 2025-06-26
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-28